Drug Pipeline News

Latest News

February 4th 2022

Michal Elovitz, MD, discusses new preterm birth data at SMFM

In this exclusive video interview, Michal Elovitz, MD, chief medical advisor at Mirvie, discusses the latest data from the RNA testing platform in predicting preterm birth at the SMFM 42nd Annual Pregnancy Meeting.

February 2nd 2022

FDA approves Cabenuva for 2 month dosing to treat HIV-1

By Ashley Gallagher

February 1st 2022

Immunotherapy approvals shine light on need for molecular testing in endometrial cancer

By Jessica Hergert

January 31st 2022

Glenmark Pharmaceuticals gets FDA approval for generic MetroGel

By Lindsey Carr, Editor

January 19th 2022

Relugolix for treating uterine fibroids

By Bob Kronemyer

CME Content

Multimedia

Community Practice Connections™: Clarifying Novel Treatment Pathways in HER2+ Breast Cancer

Neil M. Iyengar, MD; Sara M. Tolaney, MD, MPH

Mirvie RNA test aims to predict pregnancy complications

ByMorgan Ebert

January 12th 2022

Maneesh Jain, CEO and co-founder of Mirvie, a proprietary RNA platform that uses blood samples to predict pregnancy complications such as preeclampsia, sits down with Contemporary OB/GYN to discuss the potential of the test.

Agile Therapeutics announces nationwide launch of Twirla transdermal system, a new contraceptive patch

ByLindsey Carr, Editor

December 7th 2020

Agile Therapeutics, Inc. announced today the U.S. commercial launch of Twirla (levonorgestrel and ethinyl estradiol) transdermal system, a new non-daily, non-invasive contraceptive patch.